Ambrilia Biopharma Inc.

Ambrilia Biopharma Inc.

December 03, 2007 11:32 ET

Ambrilia Appoints Dr. Philippe Calais as New President and CEO


MONTREAL, QUEBEC--(Marketwire - Dec. 3, 2007) - Ambrilia Biopharma Inc. (TSX:AMB) announced today the appointment of Philippe Calais, Ph.D. Pharm., as the new President and Chief Executive Officer ("CEO"), effective January 3, 2008. Dr. Calais will also become a member of the Board of Directors, effective on the same date. The Company also announced that Richard La Rue, Vice-President, Legal Affairs, Human Resources and Corporate Secretary of Ambrilia will be resigning from the Board of Directors, effective January 3, 2008.

"We are extremely pleased to welcome Dr. Calais, who is an excellent fit for Ambrilia, as the new President and CEO," said Frederic Porte, Chairman of the Board of Ambrilia. "Dr. Calais is an accomplished biotech and pharma leader with global expertise. His broad experience in drug development combined with a global strategic marketing and alliance track record will be invaluable assets to the Company. Thus, we believe in his capability to efficiently drive implementation of our new strategy," he concluded.

"I am happy to join Ambrilia at this exciting stage in its development and look forward to leading the team as we execute our new strategic plan, aiming to become dedicated to anti-viral drug research and development by the end of 2008," said Dr. Calais. "I also look forward to working with Ambrilia's licensing partners, Merck & Co., Inc., Mallinckrodt, a Covidien Company, TEVA and others as well as forming strong relationships with the investment community," he concluded.

Ambrilia's new strategic plan entails a progressive refocus of its R&D activities in anti-virals by the end of 2008, while ensuring enhanced value for its oncology programs.


During the past two decades, Dr. Philippe Calais has gained a broad range of international expertise in management, drug development and global strategic business in the biotech and pharmaceutical industries. He has a proven track record of successes in strategy implementation and global alliances.

Dr. Calais spent most of his career at Hoffman-La Roche (Switzerland) where he occupied several executive positions and became the head of the anti-infective strategic marketing franchise. During that period he implemented a life-cycle management strategy that resulted in sustained global sales increase, and he was also in charge of global business development and licensing activities for the franchise. Dr. Calais was also sales and marketing director at the Swiss Roche affiliate, where he successfully implemented key account management. Soon after joining Hoffmann-La Roche as one of the key contributors to the R&D globalization, he was assigned to the newly created U.S. headquarters to lead the coordination of 12 R&D global projects, optimizing the development process and resource allocation from around the world. As part of his training, he also worked as a sales representative and health economics manager in the U.S. He started his career in clinical research at ICI Pharmaceuticals (France and U.K.), and was part of a major cardiovascular product registration and launch.

Dr. Calais moved to Canada to become the General Manager at Servier Canada. He successfully launched two major products and increased sales as a result of the restructuring of the Company. Prior to joining Ambrilia, Dr. Calais was President, Global Business of Neurochem, a biotechnology company focused on the development of innovative therapeutics for unmet medical needs. In that capacity, he was a key contributor to the Company's portfolio strategic direction and worldwide alliances as well as its NASDAQ listing. He was also Chairman of the Board of Neurochem International, a wholly owned subsidiary of Neurochem, where he established and managed the Company's global operations and strategic alliances.

He received his Doctorate in Pharmacy with Honours from the Universite Francois Rabelais in Tours, France, in 1987. He is currently an executive Board member of Rx&D (Canada's Research Based Pharmaceutical Companies) and of the Cite des Biotechs de Laval.


Ambrilia will be hosting a webcast at the beginning of January to introduce Dr. Calais to the financial community as Ambrilia's new President and CEO and to answer questions about Ambrilia's corporate strategic direction. Details about the webcast will be communicated closer to the date. Questions can be sent in advance of the webcast to the attention of Julie M. Thibodeau, Director, Communications at


This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the Company's filings. We refer you to the Risk Factors section of the Company's Management's Discussion & Analysis of Financial Condition and Results of Operations which contain a more exhaustive analysis of the risks and uncertainties that are generally connected to the business of the Company. Such statements are also based on various assumptions, including the successful and timely completion of clinical studies on Ambrilia's products demonstrating efficacy and safety for human use, their successful commercialization within the forecasted timelines and the attainment of the forecasted milestone payments and other revenues. While Ambrilia anticipates that subsequent events and developments may cause Ambrilia's views to change, Ambrilia specifically disclaims any obligation to update these forward looking statements, unless obligated to do so by applicable securities laws.


Ambrilia Biopharma Inc. (TSX:AMB) is a biopharmaceutical company dedicated to the discovery and development of novel treatments for viral diseases and cancer. Ambrilia's product portfolio includes an HIV protease inhibitor program (with lead compound PPL-100), an HIV integrase inhibitor program, two new formulations of existing peptides (Octreotide and Goserelin), other tumor targeted peptides such as PCK3145 and the Tumor and tumor Vasculature Targeting (TVT) technology platform, as well as other anti-viral programs. Exclusive worldwide rights to PPL-100 and its related compounds have been granted to Merck & Co., Inc. in return for milestone payments and royalties. Ambrilia's head office, research and development and manufacturing facilities are located in Montreal with a regional office in France. For more information, please visit the Company's web site:

Contact Information